Introduction
============

Because many antibiotics are administered 60 minutes before surgical incision to prevent surgical site infection \[[@B1]\], perioperative antimicrobials are typically administered before anaesthesia. Anaesthesiologists are often responsible for the administration of antibiotics in the preoperative and intraoperative periods; however, they may be unfamiliar that the administration of antibiotics is associated with the potentiation of neuromuscular blocking (NMB) agents \[[@B2]\].

Most antibiotics have been reported to cause neuromuscular block in the absence of NMB drugs \[[@B3]\]. Therefore, the use of antibiotics can prolong the duration of mechanical ventilation \[[@B4],[@B5]\]. Because some antibiotics can not only enhance NMB drug-induced muscle relaxation, but also complicate the antagonism of the neuromuscular block, control of ventilation is necessary until there is spontaneous recovery of the neuromuscular block \[[@B6]\].

Clindamycin is a 7-chloro-7-deoxy derivative of lincomycin. Clindamycin has typically been used to treat infections that are caused by anaerobic and aerobic bacteria other than enterococci \[[@B1]\]. In addition to having antibacterial effects, clindamycin produces an open ion channel block on the end-plate \[[@B7],[@B8]\] and decreases acetylcholine release at the motor nerve terminal \[[@B9]\], thus, prolonging or enhancing neuromuscular block that is caused by nondepolarizing NMB drugs \[[@B10]-[@B14]\].

While neostigmine antagonizes nondepolarizing NMB drug-induced neuromuscular block, it augments or incompletely antagonizes the NMB that is induced by combinations of some antibiotics and NMB drugs \[[@B11],[@B15],[@B16]\]. It has been demonstrated that neostigmine augments clindamycin-induced neuromuscular block \[[@B17]\]; however, it remains unclear whether neostigmine enhances the neuromuscular block that is caused by a combination of rocuronium and clindamycin.

Becker and Miller \[[@B11]\] have shown that the combination of clindamycin and d-tubocurarine or pancuronium synergistically depresses twitch tension. However, there are no reports investigating the effect of clindamycin on rocuronium-induced muscle relaxation or the interaction between clindamycin and rocuronium on neuromuscular block. The Loewe additivity model \[[@B18]\] has been established as the universal reference model for classifying drug interactions \[[@B19]\]. When the interaction index as per the Berenbaum method \[[@B20]\] is equal to, less than or greater than unity, the combination dose is labelled as additive, synergistic or antagonistic, respectively.

The intent of this study was to determine whether neostigmine potentiates the muscle relaxation that is induced by combinations of rocuronium and clindamycin and to estimate whether both clindamycin and rocuronium have synergistic actions on neuromuscular block.

Materials and Methods
=====================

The Institutional Animal Care and Use Committee approved the experimental protocol. All experimental courses followed the Guide for the Care and Use of Laboratory Animals provided by the National Academy of Sciences. Forty-one male Sprague-Dawley rats (150-250 g in weight) were anesthetized by a perivertebral injection of propofol (50 mg/kg) at the lumbar level and then killed. The phrenic nerve and diaphragm were excised together and the left diaphragm with the middle diaphragmatic ligament was separated from the rest of the diaphragm. Left phrenic nerve-hemidiaphragm preparations were mounted in a 20-ml organ bath that had been filled with Krebs solution (118 mM NaCl, 5 mM KCl, 2.5 mM CaCl~2~, 30 mM NaHCO~3~, 1 mM KH~2~PO~4~, 1 mM MgCl~2~ and 11 mM glucose). The bath solution was maintained at 32℃ and was continuously aerated with a gas mixture of 95% oxygen and 5% carbon dioxide. The pH of the bath solution was maintained at 7.38 to 7.42. Spent Krebs solution was exchanged with fresh solution 10 min after the preparation was mounted. The preparation was attached to a force transducer (Model 1030, UFI, Morro Bay, CA, USA) with a stainless steel wire and allowed to stabilize for 20 min in the bath. The phrenic nerve, connected to an electrode, was stimulated with supramaximal square wave impulses of 0.2 ms in duration using a stimulator (Model ML112, ADInstruments Pty Ltd, Bella Vista, NSW, Australia).

The diaphragm muscle was stretched until the maximum output tension was recorded after stimulation, followed by another 10 min for stabilization before the experiment began. Three consecutive single twitch tensions at 0.1 Hz and a 1.9-s tetanic tension of 50 Hz were obtained at each concentration, which were then digitized and stored on a Power Macintosh 7100 (Apple Computer Corp, Cupertino, CA, USA) using data acquisition software (MacLab, ADInstruments Pty Ltd, Bella Vista, NSW, Australia).

After baseline tensions were measured, the concentrations of rocuronium were cumulatively increased until an 80% to 90% reduction in a single twitch (ST) was reached in Krebs solution pre-treated with 0 (n = 5), 0.1 (n = 1), 0.25 (n = 1), 0.5 (n = 4) or 1.0 (n = 1) mM of clindamycin phosphate alone or in Krebs solution pre-treated with 0 (n = 4), 0.1 (n = 1), 0.5 (n = 5), 1.0 (n = 5), or 2.0 (n = 4) mM of clindamycin in combination with 250 nM neostigmine. For synergy testing, the concentrations of clindamycin were cumulatively increased until an 80% to 90% reduction in ST was reached in Krebs solution pre-treated with 0 (n = 5) or 250 nM (n = 5) of neostigmine.

A period of at least 20 min was allowed to pass to establish a pseudo-steady state condition of each drug concentration between bath and the tissue preparation. Tension measurements were made during the pseudo-steady state and in the drug-free solution after completion of each experiment. Data were analyzed only if the single-twitch tension returned to greater than 90% of the baseline recording in a drug-free solution. Single-twitch tension was calculated based on the average of three consecutive single-tension measurements. The effective concentrations (EC) of rocuronium or clindamycin for ST (percent reduction of control) and TF (tetanic fade: percent increase of TF) were determined by the probit model \[[@B17]\] and the concentration-response curves of rocuronium and clindamycin were obtained for each pre-treatment.

To evaluate the ability of neostigmine to potentiate the NMB action of clindamycin in combination with rocuronium, the potency ratios, which were equated with the EC~50~ of rocuronium with clindamycin (0.5 and 1.0 mM) to the EC~50~ of rocuronium in the absence or in the presence of neostigmine, were calculated and compared to one another.

The interaction between rocuronium and clindamycin was determined using an interaction index \[[@B20]\] from the following equation:

where c~R~ and c~Cl~ are the concentrations of rocuronium and clindamycin, respectively, both of which yield an effect, E while C~R~ and C~Cl~ are the concentrations of each drug that produce the same effect of E when given alone.

The EC~50~\'s of rocuronium given with clindamycin or those of rocuronium given with clindamycin in combination with neostigmine were compared using a Student\'s t-test with a Bonferroni\'s correction of the significance level. The EC~50~\'s of clindamycin in the absence and presence of neostigmine were compared to one another using a Student\'s t-test, and the EC~50~\'s of rocuronium with 0.5 mM clindamycin in the absence and presence of neostigmine were also compared using a Student\'s t-test. Differences were considered significant when P \< 0.05.

Results
=======

Clindamycin shifted the concentration-response curves of rocuronium to the left ([Fig. 1](#F1){ref-type="fig"} and [Fig. 2](#F2){ref-type="fig"}) as well as increased the potency of rocuronium for both a ST and TF, irrespective of the presence of neostigmine. Clindamycin at 1.0 mM moved the concentration-response curve of rocuronium in the presence of neostigmine to that of rocuronium alone ([Fig. 2](#F2){ref-type="fig"}).

To determine whether neostigmine antagonizes the neuromuscular block that is caused by combinations of clindamycin and rocuronium, the concentration-response relationships of rocuronium in combination with clindamycin or neostigmine were performed. Neostigmine at 250 nM shifted the concentration-response curve of rocuronium to the right ([Fig. 2](#F2){ref-type="fig"}), irrespective of the presence of clindamycin, and increased the EC~50~ of rocuronium with the same clindamycin concentration by approximately two-fold ([Table 1](#T1){ref-type="table"}). It was demonstrated that neostigmine partially antagonized the neuromuscular block that was induced by both clindamycin and rocuronium.

We examined the ability of neostigmine to potentiate the NMB action of clindamycin in combination with rocuronium by calculating the potency ratios of rocuronium. The potency ratios of rocuronium with neostigmine were higher than or similar to those observed in the absence of neostigmine ([Table 1](#T1){ref-type="table"}). Neostigmine failed to enhance the neuromuscular block which was induced by both clindamycin and rocuronium.

Neostigmine shifted the concentration-response curves of clindamycin to the left and enhanced the effect of clindamycin ([Fig. 3](#F3){ref-type="fig"}).

The interaction indices were less than 0.7 for a ST and TF with concentrations of clindamycin in excess of 0.5 mM without neostigmine ([Fig. 4](#F4){ref-type="fig"}). In the presence of neostigmine, the interaction indices were less than 0.7 for a ST and less than 0.9 for TF with concentrations higher than 1.0 mM of clindamycin ([Fig. 5](#F5){ref-type="fig"}). Because the interaction indices were less than one, the two drugs interacted synergistically. In view of the influence of neostigmine on the interaction index, neostigmine failed to boost the interaction of rocuronium and clindamycin.

Discussion
==========

It was demonstrated that neostigmine fails to augment the degree of neuromuscular block caused by both rocuronium and clindamycin. On the contrary, neostigmine partially antagonizes the effect of rocuronium and clindamycin combinations, whereas neostigmine reduces the rocuronium potency with both clindamycin and neostigmine less than with neostigmine alone. Therefore, neostigmine may be used to reverse the muscle relaxation that is induced by combinations of rocuronium and clindamycin.

A recent clinical report demonstrated that neostigmine fails to reverse both rocuronium and oral neomycin-induced neuromuscular block \[[@B16]\]. Edrophonium, neostigmine and pyridostigmine at sub-clinical dosages were observed to weakly antagonize the NMB of polymyxin B; however, at anti-curare dosages, they were observed to enhance the NMB \[[@B21]\]. Van Nyhuis et al. \[[@B15]\] observed that neostigmine augments the neuromuscular block caused by polymyxin B alone as well as in combination with pancuronium or d-tubocurarine. The antagonism by neostigmine and calcium may be incomplete at reversing the clindamycin-induced block \[[@B11]\] even though neostigmine augments clindamycin-induced neuromuscular block \[[@B17]\]. However, the results of this study indicate that neostigmine shifts the concentration-response curves of rocuronium to the right in the presence of clindamycin, which is a phenomenon that has not been observed for polymyxin B. The reason for this discrepancy in the response to neostigmine between clindamycin and polymyxin B is not known; however, variations in the study designs, such as the use of different NMB drugs, animal species, concentrations of neostigmine and muscles studied, in addition to possible differences between the two drugs themselves, may be potential causes.

The results of this study indicate that in rat left phrenic nerve-hemidiaphragm preparations, clindamycin enhances rocuronium-induced neuromuscular block, whether or not neostigmine is present. We found that increasing the concentration of clindamycin went together with increasing rocuronium potency and the investigated concentrations of clindamycin produced little muscle relaxation.

Clindamycin causes muscle relaxation alone \[[@B17],[@B22]\], enhances the activities of d-tubocurarine and pancuronium \[[@B11]\] in addition to prolonging the rapacuronium-induced neuromuscular block \[[@B14]\]. Consistent with what has been observed for other muscle relaxants, the results of this study indicate that clindamycin augments rocuronium-induced neuromuscular block.

Various explanations for the mechanism of clindamycin-induced neuromuscular block are diverse. Some researchers have reported that clindamycin reduces end-plate current amplitude via an exclusive decrease in the quantal content of the end-plate current \[[@B7]\]. Some researchers have found that clindamycin affects end-plate current (or potential) decay, amplitude and quantal content; they concluded that the NMB effects of clindamycin involve both pre- and post-junctional sites \[[@B8],[@B9]\]. Others have found that clindamycin post-junctionally produces a neuromuscular block by interacting with the open state of the acetylcholine-receptor (AChR) ion-channel complex \[[@B8]\]. Based on the findings of this study that augmentation of the neuromuscular block by clindamycin occurred in the presence of neostigmine, clindamycin probably blocks the open ion channels in the end-plate.

Chou and Hayball \[[@B23]\] have proposed that an interaction index between 0.9 and 1.1 designates an additive interaction. The interaction indices that were observed in this study indicate that clindamycin and rocuronium were synergistic in the depression of neuromuscular transmission according to Chou and Hayball\'s criteria.

Although it remains to be tested, several phenomena may account for the synergy of the two drugs. For example, clindamycin decreases the end-plate sensitivity to acetylcholine \[[@B24]\], increases acetylcholine receptor sensitivity to rocuronium, exerts a direct depressant action on muscle contractility \[[@B25]\], or acts with local anaesthetic activity \[[@B26]\]. Therefore, rocuronium may facilitate the channel blocking of clindamycin, or it may be that both rocuronium and clindamycin collaborate to decrease presynaptic acetylcholine mobilization, enhance AChR desensitization or influence the rates of binding to or unbinding from the AChR or the open channel \[[@B27],[@B28]\]. In addition, it has been claimed that mutually nonexclusive drugs contain an element of intrinsic synergism, which may contribute to the overall synergism \[[@B29]\]. Because they act on the different sites in AChR ion channel complex, rocuronium and clindamycin may be mutually nonexclusive and offer some degree of intrinsic synergism.

Neostigmine slightly reduces the degree of synergistic interaction between clindamycin and rocuronium. Some complicated interactions between the three drugs may occur during their presence in the neuromuscular junction. First, acetylcholine release is decreased by clindamycin and rocuronium. Second, open-channel blocking by clindamycin and AchR occlusion by rocuronium could occur postsynaptically. Finally, it is possible that a small amount of released acetylcholine limits the increase by neostigmine in the amount of acetylcholine in neuromuscular junction and prohibits opening enough channels to enhance ion-channel block of clindamycin. Thus, it may be that neostigmine fails to increase the degree of synergistic interaction between clindamycin and rocuronium.

Clindamycin potentiates rocuronium action, but only clinically produces a muscle relaxation by itself in the setting of a clindamycin overdose (2,400 mg i.v. bolus) \[[@B22]\]. A dose of 900 mg of clindamycin administered intravenously every eight hours is recommended when treating serious infections, and this dosage results in a serum concentration of 10 to 40 µg/ml (approximately 0.03 to 0.1 mM) \[[@B30]\]. The clindamycin concentrations that were studied in this investigation are approximately five to twenty times the aforementioned clinical dose and do not cause neuromuscular block.

To diminish the number of rats used, four single (n = 1) experiments were conducted. Data from each single experiment were treated as a group by correcting the significance level with Bonferroni correction. We believe these single point data should be useful in interpreting the findings that were observed in this study.

It was shown that neostigmine fails to potentiate the neuromuscular block which is caused by both clindamycin and rocuronium and can partially antagonize the neuromuscular block induced by both rocuronium and clindamycin. Clinicians should be aware that clindamycin synergistically increases the degree of rocuronium-induced muscle relaxation, even in the presence of neostigmine.

![Based on the cumulative concentration-effect curves for rocuronium on a ST at 0.1 Hz (A) and TF at 50 Hz for 1.9 seconds (B), clindamycin shifted curves to the left; thus, clindamycin augments the potency of rocuronium. Twelve preparations were studied. Rocuronium concentrations are presented as means ± SD and where a single experiment was performed (n = 1, no SD). CM: clindamycin. ^\*^Indicates P \< 0.0009, EC~50~ of rocuronium in 0.5 mM clindamycin compared to no clindamycin.](kjae-61-320-g001){#F1}

![Based on the cumulative concentration-effect curves for rocuronium on a ST at 0.1 Hz (A) and TF at 50 Hz for 1.9 seconds (B), clindamycin shifted curves to the left; hence, clindamycin augments the potency of rocuronium in the presence of neostigmine. Clindamycin at 1.0 mM shifted the concentration-response curve of rocuronium in the presence of neostigmine to the rocuronium alone curve. Rocuronium concentrations are presented as means ± SD except where a single experiment was performed (n = 1, no SD). CM: clindamycin, R alone: rocuronium in the absence of both clindamycin and neostigmine. ^\*^Indicates P \< 0.05, EC~50~ of rocuronium with 0.5 mM clindamycin and ^†^Indicates P \< 0.005, EC~50~ of rocuronium with 1.0 mM clindamycin compared to no clindamycin.](kjae-61-320-g002){#F2}

![Cumulative concentration-response curves of clindamycin in the absence (n = 6) or presence (n = 6) of 250 nM neostigmine on ST (0.1 Hz) and TF (50 Hz) for 1.9 seconds. The indicated concentrations of clindamycin represent the means ± SD of five preparations. CM, NS, ST or TF represents clindamycin, neostigmine, single twitch or tetanic fade, respectively. ^\*^Indicates P \< 0.000009 for TF, and ^†^indicates P \< 0.00004 for a ST when compared to the effect of clindamycin alone.](kjae-61-320-g003){#F3}

![Interaction indices as % inhibition of a ST are less than 0.9 with clindamycin concentrations of 0.25, 0.5 and 1.0 mM, indicating a synergistic interaction. The interaction indices with a clindamycin concentration of 0.1 mM lie between 0.9 and 1.1, indicating an additive interaction (A). The interaction indices in % increase of TF are less than 0.9 with clindamycin concentrations of 0.5 and 1.0 mM; the interaction is synergistic. The interaction indices at a clindamycin concentration of 0.25 mM lie between 0.9 and 1.1; the interaction is additive (B). Data are expressed as means ± SD except when n = 1. CM: clindamycin.](kjae-61-320-g004){#F4}

![The interaction indices as % inhibition of a ST are less than 0.9 at clindamycin concentrations of 0.5, 1.0, 2.0 and 5.0 mM, indicating the interaction between rocuronium and clindamycin is synergistic with a neostigmine concentration of 250 nM (A). The interaction indices as % increase of TF are less than 0.9 with clindamycin concentrations of 1.0 and 2.0 mM, indicating that the interaction with a neostigmine concentration of 250 nM is synergistic. The interaction indices at a clindamycin concentration of 0.5 mM lie between 0.7 and 1.1, indicating an additive interaction (B). Values are means ± SD except when n = 1. CM: clindamycin.](kjae-61-320-g005){#F5}

###### 

EC~50~ (µM) and Potency Ratios (PR = EC~50,R+CM~/EC~50,R~) for Rocuronium with Different Pre-Treatments

![](kjae-61-320-i001)

EC~50~: effective concentrations of 50% maximal effect of rocuronium, EC~50,R+CM~: EC~50~ of rocuronium with clindamycin with or without neostigmine, EC~50,R~: EC~50~ of rocuronium alone or with neostigmine, CM: clindamycin, NS: 250 nM neostigmine, R: rocuronium, ST: single twitch, TF: tetanic fade. ^\*^Indicates P \< 0.0009, versus rocuronium alone, ^†^indicates P \< 0.005, versus rocuronium with neostigmine, ^‡^indicates P = 0.02, versus PR in 0.5 mM CM + NS, ^§^indicates P = 0.05, versus PR in 0.5 mM CM + NS.
